Roivant Sciences News - May 20, 2026
🟢 ROIV is trading 11.2% up today on Q4 results and $2.25B Moderna settlement
ROIV is trading at $31.36 (+11.2%) following Q4 FY2026 results highlighted by a $2.25 billion global patent litigation settlement with Moderna. • The...
🟢 ROIV is trading 8.3% up today after a GAAP earnings beat fueled by a $770.2 million Moderna settlement gain
ROIV is trading 8.3% up at $30.54 following its Q4 earnings release, which featured a significant GAAP EPS beat despite weaker-than-expected revenue. The...
🟢 ROIV is trading 12% up today on a $2.25B Moderna settlement and Q4 earnings
ROIV is trading about 12% up at $31.50 in pre-market after reporting a massive $770.2M pre-tax gain from a $2.25B patent settlement with Moderna. • The...
Roivant's fourth quarter 2026 EPS beats on a $770.2M litigation gain, while key pipeline assets advance
Roivant reported fourth-quarter fiscal 2026 revenue of $2.52 million, below analyst estimates, while GAAP earnings per share from continuing operations was...
Roivant Sciences Reports 2026 Results, Eyes Q3 FDA Decision for Brepocitinib
Roivant Sciences reported financial results for the fourth quarter and fiscal year ended March 31, 2026. Analysts projected a loss per share between $0.29 and...